342 related articles for article (PubMed ID: 2117862)
1. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
[TBL] [Abstract][Full Text] [Related]
2. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
3. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the fibrinolytic system components during acute myocardial infarction.
Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
[TBL] [Abstract][Full Text] [Related]
5. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
6. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Collen D; Bounameaux H; De Cock F; Lijnen HR; Verstraete M
Circulation; 1986 Mar; 73(3):511-7. PubMed ID: 2419009
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Magnani B
J Am Coll Cardiol; 1989 Jan; 13(1):19-26. PubMed ID: 2491867
[TBL] [Abstract][Full Text] [Related]
8. Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
Wang Y; Liu Q; Zhu J; Yuan Z; Ma X
Chin Med Sci J; 2002 Mar; 17(1):36-9. PubMed ID: 12894883
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.
Owen J; Friedman KD; Grossman BA; Wilkins C; Berke AD; Powers ER
J Clin Invest; 1987 Jun; 79(6):1642-7. PubMed ID: 2953761
[TBL] [Abstract][Full Text] [Related]
10. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
11. New developments in thrombolytic therapy.
Collen DC; Gold HK
Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
[TBL] [Abstract][Full Text] [Related]
12. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
[TBL] [Abstract][Full Text] [Related]
13. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
[TBL] [Abstract][Full Text] [Related]
14. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
15. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
16. Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase.
Salvioni A; Marenzi GC; Agostoni P; Grazi S; Guazzi MD
Eur Heart J; 1994 May; 15(5):654-9. PubMed ID: 8056006
[TBL] [Abstract][Full Text] [Related]
17. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
[TBL] [Abstract][Full Text] [Related]
18. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
19. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
[TBL] [Abstract][Full Text] [Related]
20. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
Sherry S; Marder VJ
Ann Intern Med; 1991 Mar; 114(5):417-23. PubMed ID: 1899546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
